[go: up one dir, main page]

WO2003042661A8 - Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer - Google Patents

Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Info

Publication number
WO2003042661A8
WO2003042661A8 PCT/US2002/036810 US0236810W WO03042661A8 WO 2003042661 A8 WO2003042661 A8 WO 2003042661A8 US 0236810 W US0236810 W US 0236810W WO 03042661 A8 WO03042661 A8 WO 03042661A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
compositions
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/036810
Other languages
French (fr)
Other versions
WO2003042661A3 (en
WO2003042661A2 (en
Inventor
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Priority to AU2002357734A priority Critical patent/AU2002357734A1/en
Priority to JP2003544445A priority patent/JP2005525789A/en
Priority to EP02792272A priority patent/EP1497454A2/en
Priority to CA002467433A priority patent/CA2467433A1/en
Publication of WO2003042661A2 publication Critical patent/WO2003042661A2/en
Publication of WO2003042661A8 publication Critical patent/WO2003042661A8/en
Anticipated expiration legal-status Critical
Publication of WO2003042661A3 publication Critical patent/WO2003042661A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions.
PCT/US2002/036810 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer Ceased WO2003042661A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002357734A AU2002357734A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2003544445A JP2005525789A (en) 2001-11-13 2002-11-13 Cancer diagnosis method, cancer modulator screening composition and method
EP02792272A EP1497454A2 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA002467433A CA2467433A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33246401P 2001-11-21 2001-11-21
US60/332,464 2001-11-21
US33439301P 2001-11-29 2001-11-29
US60/334,393 2001-11-29
US33539401P 2001-12-03 2001-12-03
US60/335,394 2001-12-03
US34037601P 2001-12-14 2001-12-14
US60/340,376 2001-12-14
US34721102P 2002-01-08 2002-01-08
US60/347,211 2002-01-08
US34734902P 2002-01-10 2002-01-10
US60/347,349 2002-01-10
US35525002P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US60/355,250 2002-02-08
US35671402P 2002-02-13 2002-02-13
US60/356,714 2002-02-13
US35907702P 2002-02-20 2002-02-20
US60/359,077 2002-02-20
US36880902P 2002-03-29 2002-03-29
US60/368,809 2002-03-29
US37011002P 2002-04-04 2002-04-04
US60/370,110 2002-04-04
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
US38661402P 2002-06-05 2002-06-05
US60/386,614 2002-06-05
US39683902P 2002-07-16 2002-07-16
US60/396,839 2002-07-16
US39784502P 2002-07-22 2002-07-22
US39777502P 2002-07-22 2002-07-22
US60/397,845 2002-07-22
US60/397,775 2002-07-22
US40945002P 2002-09-09 2002-09-09
US60/409,450 2002-09-09

Publications (3)

Publication Number Publication Date
WO2003042661A2 WO2003042661A2 (en) 2003-05-22
WO2003042661A8 true WO2003042661A8 (en) 2003-10-16
WO2003042661A3 WO2003042661A3 (en) 2004-10-28

Family

ID=32097246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036810 Ceased WO2003042661A2 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Country Status (1)

Country Link
WO (1) WO2003042661A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
EP1305409B1 (en) 2000-06-16 2009-03-11 Biogen Idec MA Inc. Renal regulatory elements and methods of use thereof
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DK1401869T3 (en) 2001-06-01 2008-04-28 Biogen Idec Inc Molecules and Methods for Inhibiting Germ Excretion 1
EP2143437B1 (en) * 2001-09-18 2013-08-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040001840A1 (en) * 2002-03-04 2004-01-01 Young Paul E. Cancer-linked gene as target for chemotherapy
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2365004B1 (en) * 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CA2496781A1 (en) * 2002-08-26 2004-03-04 Case Western Reserve University Methods for treating patients and identifying therapeutics
DE60335636D1 (en) * 2002-09-11 2011-02-17 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
US7521543B2 (en) * 2002-10-23 2009-04-21 Ludwig Institute For Cancer Research A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
DK1585546T3 (en) 2002-12-30 2008-12-08 Biogen Idec Inc KIM- 1- Antagonists and Use to Modulate Immune System
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
JP2006526986A (en) * 2003-06-06 2006-11-30 アストラゼネカ・アクチエボラーグ Diagnosis method for inflammatory bowel disease
DK1644406T3 (en) 2003-07-11 2012-11-19 Develogen Ag Use of DG153 secreted protein products to prevent and treat pancreatic and / or obesity and / or metabolic syndrome
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
CA2761987A1 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005054864A2 (en) * 2003-11-22 2005-06-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 1 (kcnk1)
JP2005230011A (en) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd Breast cancer-related protein, gene encoding the same, and protein and diagnostic method for breast cancer using the gene
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2005314397A (en) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp Anti-chondromodulin-1 specific antibody and use thereof
EP1733743A4 (en) * 2004-04-09 2007-06-27 Takeda Pharmaceutical PREVENTION AGENTS / REMEDIES AGAINST CANCER
KR101200133B1 (en) 2004-06-01 2012-11-13 제넨테크, 인크. Antibody drug conjugates and methods
AU2005250185A1 (en) * 2004-06-04 2005-12-15 Laboratoires Serono Sa Splice variant of UNC5H2
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2006014999A2 (en) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
DE102004045705A1 (en) 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Uses of carbamoyl phosphate synthetase 1 (CPS) as a humoral biomarker for the diagnosis of tumors and inflammatory bowel disease
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
EP2325305B1 (en) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
CN101166542A (en) 2005-03-02 2008-04-23 比奥根艾迪克Ma公司 KIM-1 antibodies for the treatment of TH 2-mediated diseases
US20080167326A1 (en) * 2005-04-07 2008-07-10 Astrazeneca Ab Method For Assessing the Predisposition and/or Susceptibility to Copd by Analysing Fgf-Bp1
ES2533767T3 (en) 2005-04-15 2015-04-15 Epigenomics Ag Methods for the analysis of cell proliferative disorders
US20090203639A1 (en) * 2005-04-15 2009-08-13 Oncomethylome Sciences, Inc. Methylation Markers for Diagnoses and Treatment of Cancers
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
EP1897940A4 (en) 2005-05-02 2009-04-15 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSING ESOPHAGEAL CANCER AND METASTASIS OF ESOPHAGEAL CANCER
ATE533781T1 (en) 2005-05-27 2011-12-15 Bbs Bioactive Bone Substitutes Oy HEPARIN BINDING SITE CONTAINING BONE MORPHOGENETIC PROTEIN 6 AND OSTEOGENIC DEVICES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME
DK1957539T3 (en) 2005-12-08 2013-05-06 Medarex Inc HUMAN MONOCLONAL ANTIBODIES FOR PROTEINTYROSINKINASE 7 (PTK7) AND THEIR USE
PL1989231T3 (en) 2006-03-21 2015-10-30 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2007115213A2 (en) * 2006-03-30 2007-10-11 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
EP2479283B1 (en) * 2006-04-17 2016-06-22 Epigenomics AG Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2008008983A2 (en) * 2006-07-13 2008-01-17 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
EP2121738A2 (en) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
KR101290892B1 (en) 2007-07-27 2013-07-31 이매틱스 바이오테크놀로지스 게엠베하 Novel immunotherapy against neuronal and brain tumors
HUE027164T2 (en) 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
AU2012244137B2 (en) * 2007-07-27 2015-06-11 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumours
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
PE20091029A1 (en) 2007-09-26 2009-08-19 Genentech Inc ANTI-ALPHA ANTIBODIES 5 BETA 1
AU2009207645B2 (en) 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
EP2119726B2 (en) * 2008-05-14 2017-11-29 Immatics Biotechnologies GmbH Novel and powerful MHC-class II peptides derived from survivin and neurocan
WO2009142257A1 (en) 2008-05-21 2009-11-26 東レ株式会社 Composition and method for determination of esophageal cancer
KR101771714B1 (en) * 2008-05-30 2017-08-25 제넨테크, 인크. Variant hhip1 protein and methods and uses thereof
SG192517A1 (en) 2008-07-15 2013-08-30 Genentech Inc Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
KR101962476B1 (en) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 Immuno-conjugates and methods for producing them
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
MX336540B (en) 2010-06-08 2016-01-22 Genentech Inc Cysteine engineered antibodies and conjugates.
TWI524901B (en) 2010-09-29 2016-03-11 艾澤西公司 Antibody drug conjugate (ADC) that binds to the 191P4D12 protein
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Antibody and alaninyl-maitansinol conjugates
EP2699597B1 (en) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them b
KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
WO2013045464A1 (en) * 2011-09-26 2013-04-04 Roche Diagnostics Gmbh Cdna biomarkers in whole blood for colorectal cancer assessment
SI2750713T1 (en) 2011-10-14 2016-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2662808T3 (en) 2012-08-31 2018-04-09 Vasculead Inc. Peptide obtained from PSF1
BR112015008174B1 (en) 2012-10-12 2022-12-27 Medimmune Limited PYROLOBENZODIAZEPINE-ANTIBOD CONJUGATES, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATES AND USES THEREOF TO TREAT PROLIFERATIVE DISEASE AND CANCER
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
EP2766048B1 (en) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
KR101986404B1 (en) 2012-10-12 2019-06-07 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
HUE039329T2 (en) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2906251T3 (en) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
JP6445519B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
MX365742B (en) 2013-10-11 2019-06-12 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer.
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CN105873614B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
MX2016007826A (en) 2013-12-16 2017-03-31 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
NZ731782A (en) 2014-11-25 2023-04-28 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (en) 2014-12-03 2021-06-25 基因泰克公司 Quaternary ammonium compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (en) 2017-02-08 2021-06-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (en) 2017-04-18 2022-10-10 Medimmune Limited Pyrrolobenzodiazepine conjugates
ES2977788T3 (en) 2017-04-20 2024-08-30 Adc Therapeutics Sa Combination therapy with an anti-AXL antibody-drug conjugate
KR102442736B1 (en) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 Dosage regime for administration of anti-CD19 ADCs
WO2019034764A1 (en) 2017-08-18 2019-02-21 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20200055065A (en) 2017-09-20 2020-05-20 주식회사 피에이치파마 Tylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
IL282441B2 (en) 2018-10-24 2025-07-01 Hoffmann La Roche Combined chemical influencing factors of decomposition and methods of use
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (en) 2019-03-15 2024-05-06 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CN112083168A (en) * 2019-06-14 2020-12-15 复旦大学附属华山医院 Polypeptide fragment diagnosis model and application thereof in predicting medulloblastoma metastasis risk
CN110819714B (en) * 2019-11-22 2023-01-10 南方医科大学深圳医院 Cancer suppressor gene and application thereof
CN114350640B (en) * 2019-12-13 2023-09-08 中国科学院天津工业生物技术研究所 Construction of a recombinant strain expressing chitinase and screening of mutants with high enzyme activity
CN111298097B (en) * 2020-03-30 2022-05-06 山东大学齐鲁医院 Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases
CN111748623B (en) * 2020-06-08 2022-11-04 郑州大学第一附属医院 Predictive marker and kit for recurrence of liver cancer patient
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
AR128331A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE
AR128330A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE
CN114966062B (en) * 2022-07-29 2022-09-30 北京大学第三医院（北京大学第三临床医学院） Molecular marker for predicting anti-MDA 5 antibody positive dermatomyositis combined with interstitial lung disease and application thereof
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
CN119979588A (en) * 2024-12-30 2025-05-13 江南大学 A sterol C24-reductase mutant with reduced by-products and 7-dehydrocholesterol-producing yeast
CN119970996B (en) * 2025-02-25 2025-09-09 川北医学院 Application of polypeptide Angio-3 in the preparation of drugs for treating pulmonary fibrosis
CN120539414B (en) * 2025-07-31 2025-09-19 安徽医科大学 Application of FIGN protein in cytoplasm as a marker in the preparation of diagnostic products for lung adenocarcinoma and/or breast cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003042661A3 (en) 2004-10-28
WO2003042661A2 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP2261369A3 (en) Gene expression profiling in biopsied tumor tissues
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
EP2228654A3 (en) Diagnosis and prevention of cancer cell invasion
EP1365034A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
WO2003087831A3 (en) Proteins involved in breast cancer
TNSN05300A1 (en) Treatment with anti-vegf antibodies
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2003079982A3 (en) Gene amplification in cancer
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002067771A3 (en) Chemokine receptors and disease
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2004003166A3 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

WWE Wipo information: entry into national phase

Ref document number: 2002792272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467433

Country of ref document: CA

Ref document number: 2003544445

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002792272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792272

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)